Technical Analysis for IDXG - Interpace Diagnostics Group, Inc.

Grade Last Price % Change Price Change
grade C 0.9103 8.37% 0.07
IDXG closed up 8.37 percent on Monday, July 22, 2019, on 2.07 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical IDXG trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Calm After Storm Range Contraction 8.37%
Upper Bollinger Band Walk Strength 8.37%
Above Upper BB Strength 8.37%
Overbought Stochastic Strength 8.37%

Older signals for IDXG ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
PDI, Inc. provides outsourced commercial services to pharmaceutical, biotechnology, diagnostics, and healthcare companies in the United States. It operates in two segments, Commercial Services and Interpace Diagnostics. The Commercial Services segment offers outsourced sales teams that target healthcare providers, providing a range of complementary sales support services designed to achieve its customers' strategic and financial product objectives. This segment offers a range of personal and non-personal promotional options for the commercialization of their products throughout the product lifecycles, from development through maturity. It also provides other promotional services, including clinical educator, teledetailing, and full product commercialization services. This segment's services include product distribution, personal and non-personal product detailing, full supply chain management, operations, sales, marketing, compliance, and regulatory/medical management. The Interpace Diagnostics segment focuses on developing and commercializing molecular diagnostic tests for physicians and patients with diagnostic options for detecting genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. This segment offers PancraGen, a diagnostic test designed for determining risk of malignancy in pancreatic cysts; and ThyGenX, a next-generation sequencing test designed to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules. It also has three diagnostic tests in late stage development that are designed to detect genetic alterations that are associated with gastrointestinal cancers; and one diagnostic test in late stage development that is designed to detect genetic alterations that are associated with endocrine cancers. PDI, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Biotechnology Cancer Healthcare Life Sciences Biology Supply Chain Management Healthcare Providers Medical Genetics Diagnostic Tests Qiagen Gastrointestinal Cancers
Is IDXG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 1.78
52 Week Low 0.67
Average Volume 267,126
200-Day Moving Average 0.9347
50-Day Moving Average 0.7294
20-Day Moving Average 0.7456
10-Day Moving Average 0.7728
Average True Range 0.0461
ADX 35.16
+DI 40.6139
-DI 10.0915
Chandelier Exit (Long, 3 ATRs ) 0.7887
Chandelier Exit (Short, 3 ATRs ) 0.8282999999999999
Upper Bollinger Band 0.8656
Lower Bollinger Band 0.6256
Percent B (%b) 1.19
BandWidth 32.188841
MACD Line 0.0327
MACD Signal Line 0.0122
MACD Histogram 0.0204
Fundamentals Value
Market Cap 20.17 Million
Num Shares 22.2 Million
EPS -1.17
Price-to-Earnings (P/E) Ratio -0.78
Price-to-Sales 2.01
Price-to-Book 0.69
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.03
Resistance 3 (R3) 1.02 0.98 1.01
Resistance 2 (R2) 0.98 0.94 0.98 1.00
Resistance 1 (R1) 0.94 0.93 0.96 0.95 1.00
Pivot Point 0.89 0.89 0.90 0.90 0.89
Support 1 (S1) 0.86 0.86 0.88 0.87 0.82
Support 2 (S2) 0.81 0.84 0.82 0.82
Support 3 (S3) 0.78 0.81 0.81
Support 4 (S4) 0.79